Predictive Biomarkers Market Summary
The market for predictive biomarkers was valued at USD 24.30 billion in 2024 and is expected to expand at a compound annual growth rate (CAGR) of 18.02% from 2025 to 2030, reaching USD 63.54 billion. Numerous factors, including improvements in genomics and precision medicine, higher R&D spending, and a growing need for early detection and individualized therapies, are propelling the market's notable expansion.
Key Market Trends & Insights
- The North American predictive biomarker market held a revenue share of 43.83% in 2024.
- The U.S. predictive biomarker market is experiencing significant growth.
- By technology, the drug discovery and development segment is the largest segment in the predictive biomarker market, accounting for a 31.60% share in 2024.
- By indication, the cancer segment dominated the market, accounting for the largest share of revenue with 37.19% in 2024.
Market Size & Forecast
- 2024 Market SizeUSD 27.75 Billion
- 2030 Projected Market SizeUSD 63.54 Billion
- CAGR (2025-2030)18.02%
- North AmericaLargest market in 2024
- Asia PacificFastest growing market
Research and development (R&D) is a major driver of growth in the predictive biomarkers market, fueling innovation and the discovery of new biomarker candidates. Genomics and precision medicine are at the forefront of medical technology, offering the potential for more targeted and effective treatments. Predictive biomarkers can show how a person's biology or traits related to a disease might respond to treatments. The NHS and the government are making significant investments in these technologies, including the launch of the NHS Genomic Medicine Service. This service is dedicated to advancements in genomics to benefit patients by implementing genome sequencing, providing molecular diagnostics and genetic testing for cancer patients, and enhancing data integration to facilitate more effective treatments. Moreover, expertise in technology and data analytics, with proficiency in developing new sequencing technologies, is achieved through collaborations that drive innovation and advance precision medicine For instance, in April 2025, Illumina partnered with Tempus AI to accelerate the adoption of next-generation sequencing tests for patients.
The growing investment in research and development (R&D) is a key driver of the predictive biomarkers market. Pharmaceutical companies, biotech firms, and academic institutions are dedicating significant resources to discovering new biomarkers and advancing diagnostic technologies. One prominent application for biomarker identification is next-generation sequencing (NGS), which can rapidly detect millions of DNA copies within a gene. This technology enables comprehensive profiling of multiple genes and mutations in a short amount of time. For example, Illumina’s NovaSeq X platform offers high-throughput sequencing for analyzing large sequences of data and diagnosing the condition of disease. The increasing funding and collaborative efforts in biomarker discovery lead to the development of more effective and accurate predictive tests. This, in turn, is accelerating the growth of the predictive biomarkers market, supporting the next generation of healthcare innovations.
There is an increasing demand for early disease detection and personalized treatments, which is one of the key drivers in the predictive biomarkers market. Biomarkers offer important information about an individual's health, helping identify diseases in their early stages before symptoms appear. Early detection enables more effective interventions, improving patient outcomes and reducing treatment costs. An important application of predictive biomarkers is in oncology, which demonstrates resistance to treatment that continues to be a leading cause of mortality in breast cancer patients, driving the need for the development of predictive biomarkers.
New methods, like omics technologies and artificial intelligence, are being studied to find very precise molecular or imaging biomarkers that could improve treatment results. Biomarkers are even gaining popularity for incorporation into clinical trials for safety and efficacy tests. Predictive biomarkers may also become a part of these trials, tailoring medicines according to patient needs. As healthcare systems shift toward individualized medicine, predictive biomarkers play a crucial role in optimizing treatment regimens and ensuring the right therapy for each patient.
Technological drivers for predictive biomarkers in market
Technological drivers enhance the discovery, validation, and application of biomarkers by enabling faster, more accurate diagnostics and personalized treatments, accelerating the shift toward precision medicine and improving healthcare outcomes. Here are some key technological drivers in the market
Market Concentration & Characteristics
Degree of InnovationThe predictive biomarkers market is experiencing a surge in innovation, driven by advancements in genomics, proteomics, and artificial intelligence. These technologies enable the development of more accurate and personalized diagnostic tools, enhancing early disease detection and treatment efficacy. Collaborations between biotech firms and academic institutions are accelerating the discovery of novel biomarkers, particularly in oncology and neurology.
Level of M&A ActivitiesThe predictive biomarkers sectorrs sector is experiencing a moderate increase in mergers and acquisitions, as companies seek to consolidate resources and expand their technological capabilities. Strategic partnerships and acquisitions enable firms to integrate complementary expertise, access proprietary biomarker platforms, and enhance their R&D pipelines. For instance, collaborations between pharmaceutical giants and AI-driven biotech startups are fostering the development of advanced diagnostic tools.
Impact of RegulationRegulatory frameworks have a major influence on the predictive biomarkers market by ensuring the safety, efficacy, and ethical application of biomarker-based diagnostics. While stringent regulations can pose challenges, they also establish standardized protocols that facilitate market acceptance and reimbursement. Regulatory bodies are increasingly recognizing the importance of biomarkers in precision medicine, leading to the development of more streamlined approval processes. However, disparities in regulatory standards across regions can impact the global harmonization of biomarker applications, necessitating ongoing dialogue between stakeholders to align policies and promote international collaboration.
Product SubstituteThe emergence of alternative diagnostic modalities poses a challenge to the predictive biomarkers market. Technologies such as liquid biopsies, imaging techniques, and wearable health monitors offer non-invasive or minimally invasive options for disease detection and monitoring. These substitutes can complement or, in some cases, replace traditional biomarker tests, depending on the clinical context. While they provide additional tools for healthcare providers, they also intensify competition in the diagnostic space. Consequently, companies in the predictive biomarkers market must innovate continuously to maintain their competitive edge and demonstrate the unique value of their offerings.
Geographical ExpansionGeographical expansion is a key strategy for growth in the predictive biomarkers market, as companies aim to tap into emerging markets with increasing healthcare demands. Regions such as Asia, the Pacific, and Latin America present significant opportunities due to their large patient populations and evolving healthcare infrastructures. Establishing a presence in these areas allows companies to leverage local partnerships, adapt to regional healthcare needs, and navigate regulatory landscapes effectively. Additionally, entering different markets helps gather a wide range of clinical data, making biomarker-based diagnostics stronger and more useful for different groups of people.
New applications and innovations in predictive biomarkers market
New applications and innovations in the predictive biomarkers market are expanding rapidly, particularly in personalized medicine, cancer detection, and chronic disease management. Some notable developments include
-
Multi-Omics IntegrationBy bringing together data from genomics, proteomics, transcriptomics, and metabolomics, we can better understand how diseases work, which helps in finding new biomarkers and improving precise diagnostics.
-
Immunotherapy Biomarkers In oncology, predictive biomarkers are being developed to assess the effectiveness of immunotherapies, helping identify patients most likely to benefit from treatments such as checkpoint inhibitors.
-
Genomic and Proteomic Profiling Advances in sequencing technologies allow for more profound analysis of individual genomes and proteins, offering insights into complex diseases such as Alzheimer's and cancer and enabling tailored treatments.
-
CRISPR and Gene Editing Technologies The use of CRISPR technology is enabling precise gene editing to investigate disease-causing mutations. This not only aids in identifying predictive biomarkers for genetic disorders but also supports personalized treatment strategies by targeting specific genetic alterations.
-
The study of exosomes and circulating RNA as biomarkers is creating new ways to find diseases like cancer and brain disorders early on. These extracellular vesicles carry genetic information that can serve as indicators of disease.
- Biomarker DetectionEmploying nanotechnology enhances the sensitivity and accuracy of biomarker detection methods. Nanomaterials, such as nanoparticles, are used to improve the capture and analysis of biomarkers, leading to faster and more precise diagnostics, especially for cancer and infectious diseases.
These advancements represent the forefront of the predictive biomarkers market, with the potential to fundamentally change how diseases are diagnosed, treated, and managed, further enhancing the move toward personalized medicine.
Report Coverage & Deliverables
The PDF report & online dashboard will help you understand
- Competitive benchmarking
- Historical data & forecasts
- Company revenue shares
- Regional opportunities
- Latest trends & dynamics
Indication Insights
The cancer segment dominated the market, accounting for the largest share of revenue with 37.19% in 2024, driven by the growing demand for early diagnosis, personalized treatment, and monitoring of treatment responses. The ability to find specific genetic changes, protein levels, and other molecular differences in cancer cells has changed cancer treatment, making it possible to use targeted therapies and achieve better results for patients. For example, in September 2024, a Phase III trial called TROPION-Lung01 showed that a new test using computer analysis, called TROP2, could predict how well patients with non-small cell lung cancer (NSCLC) would do with the treatment datopotamab deruxtecan. This innovative biomarker assessment demonstrates the value of computational pathology in enhancing personalized treatment strategies for NSCLC. More doctors are using immunotherapies and need tests to see how well patients will respond, which is driving the growth of the predictive biomarker market in cancer care, making it the biggest and most active area in this field.
The immunological diseases segment was identified as the fastest-growing segment among all categories throughout the forecast period. Conditions such as rheumatoid arthritis, multiple sclerosis, and lupus benefit significantly from predictive biomarkers that can identify disease onset, predict flare-ups, and monitor treatment responses. Biomarkers like anti-citrullinated protein antibodies (ACPA) in rheumatoid arthritis and serum cytokines in autoimmune disorders help doctors diagnose patients and choose the right treatments, such as biologics. In July 2024, Scipher Medicine launched a new way to develop biomarkers called PRoBeNet (Predictive Response Biomarkers using Network Medicine) to help with autoimmune treatments. Advancements in genomic and proteomic profiling are improving the understanding of immunological disease mechanisms and enabling the development of personalized treatments, which are more effective and have fewer side effects. Combining the rise of biologic therapies and precision medicine, immunological diseases are becoming a major focus area for biomarker development, further expanding the market's growth potential.
Technology Insights
The drug discovery and development segment is the largest in the predictive biomarker market, accounting for 31.60% of the share in 2024, fueled by the need to enhance the efficiency and success rates of clinical trials. Predictive biomarkers enable pharmaceutical companies to identify patient subgroups most likely to respond to new therapies, reducing trial failures and accelerating regulatory approvals. These biomarkers also help in optimizing drug dosing and monitoring safety, leading to more personalized and effective treatments. Advances in genomics, proteomics, and bioinformatics are driving biomarker discovery, allowing for more precise targeting of diseases. As personalized medicine becomes the standard, the integration of predictive biomarkers into drug development pipelines is rapidly expanding, making this segment a key growth driver.
Diagnostics is the fastest-growing segment within the predictive biomarker market, driven by the increasing demand for early detection, accurate disease diagnosis, and personalized treatment plans. Predictive biomarkers are essential in identifying disease risk, guiding therapeutic decisions, and monitoring treatment response. The growing adoption of non-invasive diagnostic methods, including liquid biopsies and genomic testing, further fuels the market by offering precise, rapid, and cost-effective diagnostic solutions. With advancements in technology and an increasing focus on personalized medicine, the diagnostic application of predictive biomarkers continues to drive market growth, positioning it as the dominant segment.
Regional Insights
The North American predictive biomarker market held a revenue share of 43.83% in 2024, driven by rising chronic disease prevalence, increased demand for personalized medicine, and advancements in non-invasive diagnostic technologies. Research is accelerating market growth with continuous clinical trials for various medicinal indications. For example, in November 2022, a Phase 4 REFINE-ALS study aimed to identify predictive biomarkers to evaluate the effects of RADICAVA (edaravone) in individuals with amyotrophic lateral sclerosis (ALS), which was conducted in collaboration with the Neurological Clinical Research Institute (NCRI) at Massachusetts General Hospital (MGH). REFINE-ALS is a prospective, observational, multi-center study involving ALS patients in the U.S. and Canada who have started treatment with RADICAVA. New technologies using artificial intelligence to find biomarkers and predict how well treatments will work are speeding up market growth, along with strong support from the government and large investments in healthcare research and development.
U.S. Predictive Biomarkers Market Trends
The U.S. predictive biomarker market is experiencing significant growth driven by the rising prevalence of chronic diseases, increasing demand for personalized medicine, advanced healthcare infrastructure, and strong government and private investments in R&D. Major players lead the market through collaborations among companies. for instance, in January 2024, Genialis and Debiopharm collaborated to identify and discover biomarkers utilizing Genialis’ biology-first, machine learning-powered ResponderID platform to develop predictive biomarkers related to DNA Damage Repair (DDR) biology. Improvements in AI and machine learning are making it easier to find biomarkers, predict how well treatments will work, and develop non-invasive diagnostic tools, which is helping the market grow.
Europe Predictive Biomarkers Market Trends
The predictive biomarker market in Europe is moderately expanding, driven by rising demand for precision therapies, especially in oncology and genetic disorders; increased adoption of non-invasive liquid biopsy technologies; and strong policy support and research funding. Major players such as Thermo Fisher Scientific, Hoffmann-La Roche, Illumina, and Bio-Rad Laboratories lead the market. Advances in AI, next-generation sequencing, and liquid biopsies are enhancing biomarker discovery and personalized medicine adoption across the region.
The UK predictive biomarker market is steadily growing, driven by rising cancer and chronic disease prevalence, increasing adoption of precision medicine, and expanding healthcare infrastructure. Government support, growing investments in biomarker-based diagnostics, and collaborations between academia and industry further fuel growth. Advancements such as non-invasive testing, single-cell sequencing, and digital health tools are enhancing biomarker discovery and personalized treatment, ensuring improved patient outcomes and healthcare sustainability.
The predictive biomarker market in Germany is experiencing steady growth, driven by increasing R&D investments, expanding healthcare infrastructure, and rising incidence of cancer and genetic disorders. Strong collaborations between academic institutions, pharmaceutical companies, and contract research organizations (CROs) further fuel innovation. Key players, including Thermo Fisher Scientific, Hoffmann-La Roche, Qiagen, Illumina, Merck KGaA, and Siemens Healthineers, accelerate market growth. Research and development are gaining momentum; for instance, in May 2025, NeutroFlow had been awarded a USD 2.83 million grant from the EIC Transition Programme to advance the development of a predictive biomarker test for immunotherapy response.
Asia Pacific Predictive Biomarkers Market Trends
The Asia Pacific predictive biomarkers market is anticipated to witness the fastest growth of 19.75% CAGR over the forecast period, driven by rising chronic and non-communicable diseases, expanding precision medicine adoption, and advancements in genomics and digital health technologies. Government funding and increased R&D investments in countries such as China, Japan, India, South Korea, and Australia fuel innovation and market expansion. Technological progress in next-generation sequencing, AI-driven biomarker analysis, and non-invasive diagnostics is enhancing early disease detection and personalized treatment, positioning the region as the fastest-growing market globally.
The China predictive biomarker market is rapidly growing, driven by increasing cancer prevalence, government support for precision medicine, and rising healthcare investments. Key drivers include advancements in genomic technologies and growing demand for personalized therapies. Continuous advancements in AI and NGS (Next-Generation Sequencing) technologies further enhance predictive accuracy, fueling the competitive landscape in China’s biomarker market. Continuous advancements in AI and NGS (Next-Generation Sequencing) technologies further enhance predictive accuracy, fueling the competitive landscape in China’s biomarker market.
The Japan predictive biomarker market is experiencing significant growth, driven by an aging population, rising cancer incidence, and advancements in genomics and molecular biology. Government initiatives such as the Cancer Genome Screening Project and collaborations between academia and industry are accelerating biomarker adoption in oncology. Innovations in analytical technologies, such as next-generation sequencing, AI-driven biomarker analysis, and non-invasive diagnostics, are enhancing early disease detection and personalized medicine, strengthening Japan’s position as a leader in biomarker development and precision healthcare
Latin America Predictive Biomarkers Market Trends
The Latin America predictive biomarkers market is anticipated to grow at a substantial growth rate over the forecast period. Growth is driven by increasing prevalence of chronic diseases, rising adoption of personalized medicine, expanding digital health technologies, and government support for healthcare modernization. Key players include Thermo Fisher Scientific, Hoffmann-La Roche, Qiagen, Bio-Rad Laboratories, and Danaher Corporation. Advancements in AI, machine learning, wearable devices, and non-invasive diagnostics are accelerating biomarker discovery and improving disease management across the region.
The predictive biomarker market in Brazil is rapidly expanding, with the biomarker discovery outsourcing services segment. Growth is driven by rising demand for minimally invasive diagnostics, increasing prevalence of chronic diseases, expanding precision medicine adoption, and advancements in molecular diagnostics and bioinformatics. Innovations in AI-powered biomarker analysis, next-generation sequencing, and digital health technologies are rapidly advancing biomarker discovery and enabling more personalized treatments in Brazil.
Middle East and Africa Predictive Biomarkers Market Trends
The predictive biomarker market in the Middle East and Africa (MEA) is growing robustly due to the rising prevalence of chronic diseases such as cancer and cardiovascular conditions, advancements in genomics and molecular diagnostics, and increasing adoption of personalized medicine. Government initiatives, rising healthcare expenditure, and collaborations between research institutions and industry are further fueling market growth. Notable players in the region include Bio-Rad Laboratories, Qiagen N.V., and Merck & Co., Inc. Technological advancements like artificial intelligence and machine learning are enhancing biomarker discovery and analysis, facilitating more accurate diagnostics and treatment strategies
The Saudi Arabia predictive biomarker market is expanding rapidly, driven by increasing cancer prevalence, particularly breast cancer, and advancements in genomics and molecular diagnostics. Key drivers include government healthcare initiatives, rising awareness, and investments in precision medicine. Leading players in the market include Fujirebio, Roche, Bio-Rad, Cepheid, and Randox. Technological advancements such as next-generation sequencing (NGS) and liquid biopsy are enhancing diagnostic accuracy and treatment personalization.
Key Predictive Biomarkers Company Insights
Some of the key players operating in the market include Myriad Genetics, Inc., F. Hoffmann-La Roche Ltd., Illumina, Inc., Bio-Rad Laboratories, Qiagen NV, and Merck KGaA. Innovations in artificial intelligence, next-generation sequencing, and liquid biopsy are enhancing the accuracy and efficiency of predictive biomarker diagnostics. These developments underscore the dynamic nature of the predictive biomarker market, with established companies and emerging technologies shaping its future trajectory.
Key Predictive Biomarkers Companies
The following are the leading companies in the predictive biomarkers market. These companies collectively hold the largest market share and dictate industry trends.
- Thermo Fisher Scientific Inc.
- Qiagen
- F. Hoffmann-La Roche Ltd
- Bio-Rad Laboratories, Inc
- Illumina Inc.
- Merck KGaA
- Bio-Techne
- Siemens Healthineers AG
- PerkinElmer
- Myriad Genetics, Inc.
- Becton Dickinson
- Danaher Corporation
- Genomic Health, Inc.
- PacBio
Recent Developments
-
In August 2024, Illumina, Inc. announced FDA approval for its in vitro diagnostic (IVD) TruSight Oncology (TSO) Comprehensive test along with two companion diagnostic (CDx) indications. This approval underscores Illumina’s pivotal role in predictive biomarker development by enabling precise genomic profiling of tumors.
-
In March 2024, Volastra Therapeutics announced collaborations with Microsoft, Function Oncology, and Tailor Bio. These partnerships aim to enhance Volastra’s growing range of treatments for different types of tumors by using the discovery of predictive biomarkers.
-
In November 2023, OncoHost successfully developed a proteomics-based predictive biomarker to identify immune-related adverse events (irAEs) in patients with non-small cell lung cancer (NSCLC). OncoHost’s biomarker aids clinicians in personalizing treatment plans and mitigating risks associated with immune checkpoint inhibitors, making it an important step forward in precision oncology for NSCLC.
Predictive Biomarkers Market Report Scope
|
Report Attribute |
Details |
|
Market size value in 2025 |
USD 27.75 billion |
|
Revenue forecast in 2030 |
USD 63.54 billion |
|
Growth rate |
CAGR of 18.02% from 2025 to 2030 |
|
Actual data |
2018-2023 |
|
Forecast period |
2025-2030 |
|
Quantitative units |
Revenue in USD billion/million and CAGR from 2025 to 2030 |
|
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
|
Segments covered |
Indication, technology, region |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
|
Country scope |
U.S.; Canada; Mexico; UK; Germany; France; Italy; Spain; Sweden; Denmark; Norway; China; Japan; India; Australia; South Korea; Thailand; Brazil; Argentina; Saudi Arabia; South Africa; UAE; Kuwait |
|
Key companies profiled |
Thermo Fisher Scientific Inc.; Qiagen; F. Hoffmann-La Roche Ltd; Bio-Rad Laboratories, Inc; Agilent Technologies, Inc.; Illumina Inc.; Merck KGaA; Bio-Techne; Siemens Healthineers AG; PerkinElmer; Myriad Genetics, Inc.; Becton Dickinson; Danaher Corporation; Genomic Health, Inc.; PacBio |
|
Customization scope |
Free report customization (equivalent to up to 8 analysts’ working days) with purchase. Addition or alteration to country, regional & segment scope |
|
Pricing and purchase options |
Avail yourself of customized purchase options to meet your exact research needs. Explore purchase options |
Global Predictive Biomarkers Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, MIR has segmented the global predictive biomarkers market report on the basis of indication, technology, and region.
-
Indication Outlook (Revenue, USD Million, 2018-2030)
-
Cancer
-
Cardiovascular Diseases
-
Neurological Diseases
-
Immunological Diseases
-
Others
-
-
Technology Outlook (Revenue, USD Million, 2018-2030)
-
Diagnostics
-
Drug Discovery & Development
-
Personalized Medicine
-
Disease Risk Assessment
-
Others
-
-
Regional Outlook (Revenue in USD Million, 2018-2030)
-
North America
-
U.S.
-
Canada
-
Mexico
-
-
Europe
-
UK
-
Germany
-
France
-
Italy
-
Spain
-
Sweden
-
Denmark
-
Norway
-
-
Asia Pacific
-
Japan
-
China
-
India
-
Australia
-
South Korea
-
Thailand
-
-
Latin America
-
Brazil
-
Argentina
-
-
Middle East and Africa
-
Saudi Arabia
-
South Africa
-
UAE
-
Kuwait
-
-
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy